Find the Perfect Plan for Your Investment Journey
A
Latest price
52 Week Range
€1.00 - €1.50
Next Earnings Date
Sep 24 2025 (Estimate)
Next Earnings Date
Sep 24 2025 (Est.)
Latest price
Market Cap | €41.96M |
EV | €41.48M |
Shares Outstanding | 34.68M |
Beta | 1.02 |
Analyst Rating | BUY |
Analyst Target Price | €10.75 |
P/E 2025E | - |
P/Revenue 2025E | 9.24x |
Revenue | 87.30% |
EPS | 17.30% |
Operating Cash Flow | 18.70% |
Free Cash Flow | 18.80% |
Revenue | 38.00% |
EPS | -4.90% |
Operating Cash Flow | -34.60% |
Free Cash Flow | -34.30% |
Gross Margin 2025E | 10.00% |
Net Profit Margin 2025E | -189.13% |
ROE 2025E | - |
ROCE 2024 | -56.76% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
A
ABIONYX Pharma SA
ABNX
Sector
Healthcare
Industry
Biotechnology
CEO
Tupin, Cyrille
Employees
51
Website
abionyx.comIPO Date
2015-03-30
Headquarters
33 43 av. Georges Pompidou Bât. D2, Balma, Midi-Pyrénées, 31130, France
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved